1[1]Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease[J]. Ann thorac surg, 1999, 68(3):830-836.
2[2]Laugwitz KL, Ungerer M, Schultz G, et al. Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes[J]. Circulation, 1999, 99(7):925-933.
3[3]Schmidt U, Monte F, Miyamoto MI, et al. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca[2+]-ATPase[J]. Circulation, 2000, 101(7):790-796.
4[4]Maurice JP, Hata JA, Glower DD, et al. Enhancement of cardiac function after adenoviral-mediated in vivo introcoronary β2-adrenergic receptor gene delivery[J]. J Clin Invest, 1999, 104(1):21-29.
5[5]Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy:the PREVENT single-centre, randomised, controlled trial[J]. Lancet, 1999, 354(9189):1493-1498.
6[6]Schwartz LB, Moawad J, Svensson EC, et al. Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts[J]. J Vasc Surg, 1999, 29(5):874-881.
7[8]Schwartz LB, Moawad J. Gene therapy for vascular disease[J]. Ann Vasc Surg, 1997, 11:189-199.
8[9]LI Huiqin, Chavin KD, Yao Zhongding. Adenovirus-mediated gene transfer to biral IL-10 gene prolongs murine cardiac allograft survival[J]. J Immunol, 1996, 156(6):2316-2323.
9[10]Kaplan JM, St George JA, Pennington SE, et al. Humoral and cellular immune responses to Ad2/CFTR-2[J]. Gene Ther 1996, 3(2):117-127.
10[11]Christ M, Lusky M, Stieckel F, et al. Gene therapy with recombinant adenovirus vectors:evaluation of the host immune response[J]. Immunol Lett, 1997, 57(1997):19-25.
